Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Biogen Stock News

BIIBNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

Biogen (BIIB) Forecast

News

Earnings Biogen (BIIB) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest Biogen Stock News | NASDAQ:BIIB | Benzinga

Get the latest news on Biogen stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Biogen performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, May 16, 2025

'FDA Clears First Blood Test Used In Diagnosi...
Benzinga Newsdesk

Wednesday, May 14, 2025

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
Piero Cingari

Wednesday, May 07, 2025

Mizuho Maintains Outperform on Biogen, Lowers...
Benzinga Newsdesk

Monday, May 05, 2025

JP Morgan Maintains Neutral on Biogen, Lowers...
Benzinga Newsdesk

Friday, May 02, 2025

RBC Capital Maintains Outperform on Biogen, L...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Biogen, Lo...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Biogen, ...
Benzinga Newsdesk
Baird Maintains Outperform on Biogen, Lowers ...
Benzinga Newsdesk
Needham Reiterates Hold on Biogento Hold
Benzinga Newsdesk

Thursday, May 01, 2025

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Vandana Singh
Biogen Lowers FY2025 Adj EPS Guidance from $1...
Benzinga Newsdesk
Biogen Q1 Adj. EPS $3.02 Beats $2.52 Estimate...
Benzinga Newsdesk
Earnings Scheduled For May 1, 2025
Benzinga Insights

Tuesday, April 29, 2025

Truist Securities Maintains Buy on Biogen, Lo...
Benzinga Newsdesk
Piper Sandler Maintains Neutral on Biogen, Lo...
Benzinga Newsdesk

Friday, April 25, 2025

Needham Reiterates Hold on Biogento Hold
Benzinga Newsdesk

Wednesday, April 23, 2025

Goldman Sachs Maintains Buy on Biogen, Lowers...
Benzinga Newsdesk

Tuesday, April 22, 2025

14 Analysts Have This To Say About Biogen
Benzinga Insights
RBC Capital Maintains Outperform on Biogen, R...
Benzinga Newsdesk

Wednesday, April 16, 2025

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Vandana Singh
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
Vandana Singh
Needham Reiterates Hold on Biogento Hold
Benzinga Newsdesk
Reported Earlier, European Commission Approve...
Benzinga Newsdesk

Wednesday, April 09, 2025

Morgan Stanley Maintains Equal-Weight on Biog...
Benzinga Newsdesk

Friday, April 04, 2025

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Vandana Singh
What 14 Analyst Ratings Have To Say About Biogen
Benzinga Insights
Argus Research Downgrades Biogen to Hold
Benzinga Newsdesk

Wednesday, April 02, 2025

Biogen Says FDA Granted Fast Track Designatio...
Benzinga Newsdesk

Tuesday, April 01, 2025

Organon Acquires Regulatory And Commercial Ri...
Benzinga Newsdesk

Friday, March 28, 2025

European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Vandana Singh

Monday, March 24, 2025

Biogen Plans For Its New Global Headquarters ...
Benzinga Newsdesk

Friday, March 21, 2025

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Vandana Singh

Wednesday, March 19, 2025

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Vandana Singh

Tuesday, March 11, 2025

Biogen Begins Phase 3 Study Of Felzartamab Fo...
Benzinga Newsdesk

Monday, March 10, 2025

Decoding Biogen's Options Activity: What's the Big Picture?
Benzinga Insights

Friday, March 07, 2025

How Is The Market Feeling About Biogen?
Benzinga Insights

Thursday, March 06, 2025

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Vandana Singh

Tuesday, March 04, 2025

What the Options Market Tells Us About Biogen
Benzinga Insights

Monday, March 03, 2025

Eisai and Biogen Announces That The Therapeu...
Benzinga Newsdesk

Friday, February 28, 2025

The CHMP Reaffirms Positive Opinion For Lecan...
Benzinga Newsdesk

Monday, February 24, 2025

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Vandana Singh

Friday, February 21, 2025

Biogen Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights

Tuesday, February 18, 2025

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Vandana Singh
Piper Sandler Reiterates Neutral on Biogen, L...
Benzinga Newsdesk
Biogen And Stoke Therapeutics Enter Into Coll...
Benzinga Newsdesk

Thursday, February 13, 2025

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Vandana Singh
Scotiabank Maintains Sector Outperform on Bio...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Bioge...
Benzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Biog...
Benzinga Newsdesk
Goldman Sachs Maintains Buy on Biogen, Lowers...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved